Zhaoke Ophthalmology Limited (06622.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

Market Cap

HKD 1.38B

MomentumView details →

1D Return

+1.61%

YTD Return

−14.53%

RSI (14)

49.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

Market Cap

HKD 1.38B

RSI (14)

49.3

MomentumView details →

1D Return

+1.61%

YTD Return

−14.53%

ProfitabilityView details →

Gross Margin

−25.66%

Net Margin

−701.58%

EBITDA Margin

−731.62%

ROE (TTM)

−35.44%

ROA (TTM)

−28.31%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+2.32%

EPS YoY

+31.82%

FCF YoY

+63.94%

Revenue CAGR 3Y

+28.89%

EPS CAGR 3Y

+13.95%

EBITDA YoY

+31.51%

EarningsView details →

EPS (Actual)

−HKD 0.25

EPS Surprise

11.84%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.53

Avg Surprise (4Q)

11.84%

Rev Surprise

398.28%

Capital & dividendView details →

Debt/Equity

0.19x

Current Ratio

3.41x

Quick Ratio

3.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

70.11M

Net Income (TTM)

−491.86M

Op. CF (TTM)

—

Next earningsMar 29, 2027 →

Latest newsMore news →

Zhaoke Ophthalmology signed an exclusive distribution and promotion agreement with Pengpai Biomedical for its epinastine hydrochloride eye drops (brand: Mingyanshu) covering all sales channels in mainland China, with an initial five-year term and possible extension to ten years.24d ago

Similar companies

Odyssey Therapeutics, Inc.ODTX Alto Neuroscience, Inc.ANRO Omeros CorporationOMER ImmuneOnco Biopharmaceuticals (Shanghai) Inc.01541.HK Replimune Group, Inc.REPL Immatics N.V.IMTX Find similar companies →

Latest newsMore news →

Zhaoke Ophthalmology signed an exclusive distribution and promotion agreement with Pengpai Biomedical for its epinastine hydrochloride eye drops (brand: Mingyanshu) covering all sales channels in mainland China, with an initial five-year term and possible extension to ten years.24d ago